PDCD1 and non-small cell lung carcinoma: Our study examined immunosuppressive markers (including PD-1 and TIM-3) on peripheral blood T cells and their subsets (including αβT and γδT cells) in NSCLC patients receiving chemotherapy combined with anti-PD-1 therapy, and monitored the cytokine levels in the peripheral blood.